 Glaukos Corp NYSE: GKOS has announced topline data from the U.S. Phase 3 trial evaluating its corneal cross-linking iLink therapy to treat keratoconus. Keratoconus is characterized by cone-shaped cornea causing blurred vision and sensitivity to light and glare. 